Certificate of Analysis & Product Manual

Triple Repeat Disorders Genotyping
Fragile X, Myotonic Dystrophy, Friedreich's Ataxia, Huntington's disease
Fluorescent Probes, siRNA, Hybridization and Detection Reagents



Myotonic Dystrophy CTG Repeat Genotyping GeneProber™ GLDMDig2

Myotonic Dystrophy CTG triple repeat chemiluminescent Southern blot genotyping

Catalog No. 40-2026-41

Storage Condition: -20°C

For Research Use Only. Not for use in diagnostic procedures for clinical purposes

Important Information

All Gene Link products are for research use only. Not for use in diagnostic procedures for clinical purposes.

Product to be used by experienced researchers appropriately trained in performing molecular biology techniques following established safety procedures. Additional qualification and certification is required for interpretation of results.



Material Supplied

Myotonic Dystrophy CTG Repeat Genotyping GeneProber™ GLDMDig2

	Catalog No.	Description	Size
REF	40-2026-41	Myotonic Dystrophy GLDMDig2 GeneProber™ Digoxigenin	110 μL
		labeled	


Certificate of Analysis & Product Specifications

One tube containing 110 μ L of Myotonic Dystrophy GeneProberTM GLDMDig2 probe at a concentration of ~40ng/uL. This probe is digoxigenin labeled for non-radioactive detection. The quantity supplied is sufficient for at least 5 20x20 cm blots using 20 μ L for each blot as probe.

The Myotonic Dystrophy GeneProber™ GLDMDig2 probe supplied has been validated to hybridize to the CTG triple repeat spanning region in the *DMPK* gene of human genomic DNA digested with EcoRI, BgII, BamHI or PstI.

Appropriate nuclease free handling, dispensing and storage conditions required.

Product Label Information





GeneProber™ Related Product Ordering Information

The GeneProber™ product line is based on the chemiluminescent Southern blot detection method. Gene Link's non-radioactive detection systems for genotyping of triple repeat disorders are rapid, reliable and as sensitive as the ³²P labeled southern blots. No more decayed probes and radioactive exposure. Kits are available for reliable genotyping of the Fragile X, Huntington's Disease, Myotonic dystrophy and other triple repeat mutation group disorders.

Unlabeled GeneProber™ probes are also available for radio labeling and radioactive based detection. Gene Link strongly recommends the use of non-radioactive gene detection systems. Consider switching to Gene Link's product line of non-radioactive detection systems.

Product	Unit Size	Catalog No.
Fragile X GeneProber™ GLFX1 Probe unlabeled	500 ng	40-2004-40
Fragile X GeneProber™ GLFXDig1 Probe Digoxigenin labeled	110 μL	40-2004-41
FRAXE/FMR2/AFF2 GeneProber™ AFF2-AJ31Dig1	110 μL	40-2054-41
Huntington's Disease GeneProber™ GLHD14 Probe unlabeled	500 ng	40-2025-40
Huntington's Disease GeneProber™ GLHDDig2X Probe Digoxigenin labeled	110 μL	40-2025-41
Myotonic Dystrophy GeneProber™ GLDM1 Probe unlabeled	500 ng	40-2026-40
Myotonic Dystrophy GeneProber™ GLDMDig2 Probe Digoxigenin labeled	110 μL	40-2026-41
Friedreich's Ataxia GeneProber™ GLFRDA21 Probe unlabeled	500 ng	40-2027-40
Friedreich's Ataxia GeneProber™ GLFRDADig21 Probe Digoxigenin labeled	110 μL	40-2027-41
Mitochondrial DNA deletion GeneProber™ GLmtDNA2.5Dig1 Probe Digoxigenin labeled	110 μL	40-2055-41

GScan™ Related Product Ordering Information

Gene Link's GScan™ gene detection products are safe, convenient and sensitive, and afford automated compilation of data. Kits are available for reliable genotyping of the Fragile X, Huntington's Disease, Myotonic dystrophy and other triple repeat mutation group disorders. The kits contain optimized PCR amplification reagents and a wide array of fluorescent-labeled primers for genotyping after PCR using fluorescent genetic analyzer instrument. Included in these kits are ready-to-run control samples of various repeats of the triple repeat disorder kit. These control samples are for calibration with the molecular weight markers for accurate size determination of the amplified fragments.

The GScan™ kits are simple and robust for routine triple-repeat detection of greater than 100 repeats of all triple repeat disorders listed.

Product	Unit Size	Catalog No.
Fragile X GScan™ V2 Kit for fluorescent detection; 100 reactions kit	1 kit	40-2004-15XX
ragile X GScan™ V2 Kit for fluorescent detection; 20 reactions kit	1 kit	40-2004-15FMS
RAXE/FMR2/AFF2 GScan™ Kit for fluorescent detection; 100 reactions kit	1 kit	40-2054-15FM
RAXE/FMR2/AFF2 GScan™ Kit for fluorescent detection; 20 reactions kit	1 kit	40-2054-15FMS
Huntington's Disease GScan™ V2 Kit for fluorescent detection; 100 reactions kit	1 kit	40-2025-15XX
Huntington's Disease GScan™ V2 Kit for fluorescent detection; 20 reactions kit	1 kit	40-2025-15FMS
Myotonic Dystrophy GScan™ Kit for fluorescent detection; 100 reactions kit	1 kit	40-2026-15XX
Myotonic Dystrophy GScan™ Kit for fluorescent detection; 20 reactions kit	1 kit	40-2026-15FMS
riedreich's Ataxia GScan™ Kit for fluorescent detection; 100 reactions kit	1 kit	40-2027-15XX
riedreich's Ataxia GScan™ Kit for fluorescent detection; 20 reactions kit	1 kit	40-2027-15FMS

All Gene Link products are for research use only



Myotonic Dystrophy Genotyping

Background

Myotonic dystrophy (**Dystrophia Myotonica, DM**) is the most common form of adult onset muscular dystrophy. It is an autosomal dominant disorder with a prevalence of about 1 in 8000. The incidence varies from 1 in 475 in a region of Quebec to about 1 in 25,000 in European populations and is extremely rare in African populations. Clinical expression is highly variable and is related to age of onset. Onset of this disorder commonly occurs during young adulthood. However, it can occur at any age and is extremely variable in degree of severity. Myotonic dystrophy affects skeletal muscle and smooth muscle, as well as the eye, heart, endocrine system, and central nervous system. People with the mildest form of DM often go undiagnosed and usually cataracts and minimal muscle involvement are the only visible sign of the condition. The classical form of DM usually develops in early adult life and is characterized by progressive muscle stiffness and weakness.

Congenital DM (CDM) is the most severe form of the disease and is almost always inherited from affected mothers. It presents in newborn babies who suffer from respiratory distress, hypotonia, motor and mental retardation and facial diplegia. Diagnosis can be difficult if the family history is not known because muscle wasting may not be apparent and cataracts and myotonia are absent. CDM patients who survive the neonatal period eventually learn to walk but 60-70% are mentally retarded. By the age of 10 they develop myotonia and in adulthood they develop the additional complications associated with adult onset disease.

Identification of the mutation in DM

The myotonic dystrophy gene locus and the underlying mutation were identified in 1992 (1-3). An expressed sequence called cDNA25 was shown to detect a two-allele *Eco*RI polymorphism (8.6kb and 9.8kb) on Southern blots of normal individuals. It also detects a larger variable fragment in DM patients, which can be up to 5kb longer than the larger, normal allele. When this fragment is transmitted from an affected parent, it often increases in size, correlating well with the severity of the disease in the affected child. The variable band can also show somatic heterogeneity in lymphocyte DNA that is seen as a diffuse smear on a Southern blot. The *Eco*RI polymorphism is due to the insertion or deletion of consecutive Alu repeats 5 kb distal to the unstable region – the 8.6kb allele contains two Alu repeats and the 9.8kb normal allele and the enlarged DM alleles are associated with five Alu repeats. The discovery of unstable DNA at the DM locus provided an explanation for the phenomenon of anticipation seen in DM. Sequence analysis of genomic clones spanning the expanded region revealed that the mutation causing the instability is a trinucleotide repeat (CTG) which is highly polymorphic in the normal population and which increases dramatically in length in DM patients.

Number of CTG repeats	Clinical Condition	Symptoms
5-27 repeats	unaffected	
50-100 repeats	mild:	cataracts, slight muscle problems later on in life
100-1000 repeats	classical:	myotonia, muscle wasting, premature balding, gonadal atrophy, cardiac conduction defects
1000-4000	congenital:	hypotonia, mental retardation, facial diplegia



There are no definite repeat size boundaries for the three clinical groups and there are overlaps between the groups. A trimodal distribution is observed in European populations, with (CTG)₅ being the most frequently occurring allele, alleles of 11,12,13 and 14 make up the second mode and the final mode represents alleles of 19 and above.

Meiotic instability

The meiotic instability of the DM mutation has been shown to be dependent on the size of the parental repeat. For $(CTG)_n$ repeats of <0.5kb a positive correlation between the size of the repeat and inter-generational enlargement was found equally in male and female meioses but with CTG sequences of more than 0.5 kb observed that intergenerational variation was greater through female meioses (4). The tendency for a repeat to undergo contraction was observed almost exclusively in male meioses. It was found that the length of the CTG repeat expansion in DM patients was greater in DNA isolated from muscle than in lymphocyte DNA (5). Rare cases have been reported where expansion of the CTG repeats is not seen in individuals where the clinical symptoms are unequivocal and this may due to a deletion or point mutation as seen in some of the other triplet repeat disorders such as fragile X syndrome.

The underlying mutations of DM are expansions of the CTG repeats located in the 3' untranslated region (UTR) of the myotonic dystrophy protein kinase (*DMPK*) gene on chromosome 19q. Severity of the disease is correlated with the length of the repeat expansion. Normal individuals have from 5 to 27 repeat copies; mildly affected persons have at least 50 repeats, while more severely affected patients have expansion of the repeat-containing segment up to several kilobase pairs.


Expansion is frequently observed in parent-to-child transmission, but extreme expansions are not transmitted through the male line. This explains: 1.) the occurrence of the severe congenital form is almost exclusively in the offspring of affected women; 2.) anticipation is commonly observed in affected families, that is, the disease demonstrates earlier onset and greater severity in each successive generation. The overall risk of having a congenitally affected child for any carrier woman is about 10%. If the woman has clinical signs of the condition, the risk of congenital myotonic dystrophy in offspring is 40% and this rises to 50% in subsequent pregnancies if an affected child has previously has been born.

Genotyping

Molecular Analysis

The direct analysis of CTG repeats in the *DMPK* gene (chromosomal locus 19q13) is available. Molecular diagnosis of myotonic dystrophy involves a combination of direct PCR analysis and Southern blotting tests to determine the CTG-repeat number within the DMPK gene. PCR can identify CTG expansions between 5-200 CTG repeats. Congenital mutations usually cannot be identified by PCR and southern analysis is the preferred method to distinguish full mutations.


With larger expansions, Southern blot analysis of restriction fragments can be used to determine the range of the large repeat size. Genomic DNA is digested with BgII I, BamHI or PstI or/and EcoRI to determine the presence or absence of the ~1 kb Alu repeat. The DNA blot is then hybridized with either Gene Link's GLDMDig2 Digoxigenin labelled probe for non-radioactive chemiluminescent detection or for radioactive Southern Blot by using random prime labelled Gene Link's GLDM4 probe. Both of these probes are specifically designed to exclude the CTG repeat region to yield very low background specific hybridization signals to the fragments containing the CTG repeat.



The size of the CTG repeats can be determined by PCR analysis and sizing preferably on a sequencing gel or fluorescent fragment analyzers. The PCR products can be either labeled with ³⁵S or ³²P followed by autoradiography. Another attractive alternate is to run a cold PCR reaction followed by blotting and hybridization with an alkaline phosphatase conjugated probe for non-radioactive detection.

Southern blot analysis for Myotonic Dystrophy mutation detection involves the cleavage of DNA with Bgll, BamHI or PstI enzyme combined with EcoRI to determine the 1 Kb Alu repeat genotype. This method detects the size of CTG repeats region by hybridization of Gene Link's probe GLDM1, GLDM2, GLDM3 or GLDM4 to DNA that has been digested with the appropriate restriction enzyme and blotted onto a membrane.

Gene Link Myotonic Dystrophy GeneProber[™]




DMPK Gene Normal Southern Blot Fragment Analysis Pattern Restriction Digestion*		
Restriction Enzyme	Normal Fragment Size	
EcoRI	~8.9 or/and 9.9 kb	
Bgll	~3.4 kb	
BamHI	1.37 kb	
Pstl	1.13 kb	
*Probed with Gene Link DMPK CTG repeat region specific probes GL DMDig2, DM3 and DM4.		

Gene Link offers safe and reliable chemiluminescent detection methods as an alternate to radioactive based detection methods. Genemer™, PCR-Prober™, GScan™ and GeneProber™ line of products replaces radioactive based methods. Gene Link's GScan™ and Genemer™ kits are for PCR amplification followed by agarose gel electrophoresis or fluorescent fragment length detection of the specific triple repeat fragment size and routinely detects greater than 120 CGG repeats for fragile X.

Genemer™ Kit Agarose Gel Analysis

Optimized Genemer™ kit with components for PCR amplification of up to ~400 CGG repeats using standard Taq polymerase. Amplified samples are resolved by agarose gel electrophoresis. This Genemer™ method or GScan™ fluorescent detection is recommended for initial screening of all samples.




GScan™ Kit

Optimized GScan™ kit with components for PCR amplification of up to ~400 CGG repeats using standard Taq polymerase. Amplified samples are resolved by fragment analyzers capable of fluorescent detection or agarose gel electrophoresis. This Genemer™ Kit or GScan™ kit for fluorescent detection is recommended for initial screening of all samples.

GeneProber™ Probes for Southern Blot Analysis

Digoxigenin labelled probes for chemiluminescent Southern blot detection method or unlabeled probe for end user to perform radioactive label. Gene Link offers safe and reliable chemiluminescent detection methods as an alternate to radioactive based detection methods.



References

- 1. Fu YH, Pizzuti A, Fenwick RG Jr, King J, Rajnarayan S, Dunne PW, Dubel J, Nasser GA, Ashizawa T, de Jong P, et al. (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255: 1256-1258.
- 2. Aslanidis et al. (1992) Cloning of the essential myotonic dystrophy region and mapping of the putative defect. Nature 355: 548-551.
- 3. Brook et al. (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3-prime end of a transcript encoding a protein kinase family member. Cell 68: 799-808.
- **4.** Lavedan et al. (1993) Myotonic dystrophy: size- and sex-dependent dynamics of CTG meiotic instability, and somatic mosaicism. Am. J. Hum. Genet. 52: 875-883.
- 5. Anvret et al. ((1993) Larger expansions of the CTG repeat in muscle compared to lymphocytes from patients with myotonic dystrophy. Human Molecular Genetics 2:1397-1400.
- **6.** Mathieu J, Allard P, Potvin L, Prevost C, Begin P (1999) A 10-year study of mortality in a cohort of patients with myotonic dystrophy. *Neurology* 52:1658-62
- 7. Redman JB, Fenwick RG Jr, Fu YH, Pizzuti A, Caskey CT (1993) Relationship between parental trinucleotide GCT repeat length and severity of myotonic dystrophy in offspring. *JAMA* 269:1960-5



Procedure: Chemiluminescent Southern Protocol

Material Supplied

One tube containing 110 μ L of GLDMDig2 GeneProberTM probe at a concentration of ~40ng/ μ L. This probe is digoxigenin labeled for non-radioactive detection. The quantity supplied is sufficient for at least 5 20x20 cm blots using 20 μ l for each blot as probe. Experienced users can save and reuse the hybridization solution 2-3 times.

A. Chromosomal DNA digestion

-Digest genomic DNA with your laboratory's preferred fragment analysis restriction enzyme for myotonic dystrophy CTG repeat genotyping.

Restriction Digestion				
Volume Quantity				
5 to 10μg				
10 μL				
4 μL				
100 μL				

♦ Incubate over night at 37^oC

♦ Ethanol Precipitate the digests

- -To 100 μL DNA add 10 μL of 3M Na Acetate pH 5.2
- -Add 2 volumes (250 μL) of 100% ethanol
- -Put in the freezer (-20 °C) for 20-30 minutes
- -Spin at -10 °C for 5 minutes
- -Discard the supernatant
- -Add 100 µL of 70% ethanol, vortex.
- -Spin again at -10 °C for 5 minutes
- -Dry samples
- ♦ Dissolve the pellets in 10 μL of 1x loading buffer

B. Electrophoresis and Transfer

- 1. Load samples to a 0.8% agarose gel. Electrophorese over night at 45mA for 20-24 hours. (1.6 kb fragment on the bottom of the gel).
- 2. Depurinate with 0.25N HCl (add 10 mL HCl to 500 ml H_2O) for 10 minutes.
- 3. Denature the DNA with 0.4N NaOH/0.6M NaCl for 30 min. at room temperature (RT).
- 4. Neutralize with 1.5M NaCl/0.5M Tris (pH 7.5) for 30 min. at RT.
- 5. Transfer overnight by Southern blot procedure to positively charged nylon membrane using 10xSSC.
- 6. Wash the membrane with 2x SSC and then bake at 80^oC for 2 hours.



C. Hybridization

- 1. Perform prehybridization at 55°C for 3 hours in 10 mL of Easy Hyb buffer (Roche Biochemicals).
- 2. Boil 20µL GeneProber™ probe in 500µL of Easy Hyb for 10 minutes. Chill directly on ice.
- 3. Add the above probe to 10mL of Easy Hyb.
- 4. Discard the prehybridization buffer and replace it with the hybridization buffer containing the boiled probe. Hybridize overnight at 55° C.
- 5. Washing. Wash the membrane in 2xSSC/0.1% SDS at RT twice (5 min/wash), 0.5xSSC, 0.1%SDS twice at 65°C to 70°C (15 min/wash).
- 6. Warm the blocking reagent at this point. Prepare fresh 100 mL of Buffer MB by adding 10 mL of 10% blocking reagent [Gene Link Catalog no: 40-5026-10; Blocking solution for hybridization (10%)] and 10 mL of Maleic acid buffer 10X (Buffer M 10X) [Gene Link Catalog no: 40-5025-20; Maleic acid buffer 10X (Buffer M 10X)] to 80 mL of sterile water. Use 80 mL for blocking and the rest of 20 mL for making Anti-DIG-AP conjugate.

D. Anti-Dig Alkaline Phosphatase Binding

- 1. Equilibrate the membrane in 100 mL of 1x washing buffer M for 1 minute.
- 2. Incubate the membrane in 80 mL of Buffer MB (prepared in step 6 above) blocking solution at RT for 30 min.
- 3. Prepare 1:10000 Anti-DIG-AP conjugate at this point. Example, add 2 μ l to 20 ml Buffer MB (prepared in step 6 above).
- 4. Incubate the membrane in 20 mL of Anti-DIG-AP conjugate solution at RT for 30 min.
- 5. Wash the membrane twice, 15 min/wash in 200 mL of 1x washing buffer M at RT.
- 6. Equilibrate the membrane in 50 mL of 1x Detection buffer for 2 min. Repeat 2 times. Total of three washes.

E. Detection

Detection with CDP star (Tropix) as substrate will yield reliable result by exposing to Kodak X-OMAT or XAR X-ray film for 1 hour to overnight at room temperature.


Transfer blot to a plastic sheet, (sheet protector cut from two sides to open up) and drain off excess buffer. Wipe off edges with paper towel. Blot should not be allowed to dry.

Spray CDP-star ready-to-use substrate evenly to cover the blot. DO NOT OVER SPRAY. Cover the blot with plastic sheet and wipe entire surface of the covered blot to expel any excess substrate and air bubbles. Expose the film at room temperature for 1 hr. or for shorter or longer time as required.

Luminescence continues for at least 24 hours and signal intensity remains almost constant during the first few hours. Multiple exposures can be taken to achieve the desired signal strength.

F. Stripping

Wash the membrane in water to remove the substrate. Then wash the membrane in 0.2N NaOH/0.1% SDS at 37° C for 30 minutes. Rinse the membrane in 2XSSC. Air dry.




Results and Analysis

Gene Link's Myotonic Dystrophy CTG repeat Southern blot genotyping probes GLDMdig2, GLDM3 and GLDM4 are especially designed to exclude the CTG repeat region and thus yield cleaner blot with less background as compared to other probes including Gene Link's older GLDM1 and GLDM2 probes.

Traditionally Southern blot analysis for Myotonic Dystrophy CTG repeat genotyping involves the cleavage of DNA with restriction enzymes EcoRI and BgII. EcoRI digested DNA detects the presence or absence of the ~1kb Alu polymorphism, the detection of this polymorphism is not essential for genotyping the CTG repeat status except to have additional data for the Alu polymorphism status. EcoRI Southern blot analysis alone is not recommended as it may mask mid-range CTG expansion. If EcoRI Southern blot analysis is performed then it should always be in conjunction with an additional blot analysis with BgII, BamHI or PstI.


BgII, BamHI or PstI Southern blot analysis is the preferred method to supplement the PCR genotyping results. These restriction enzymes yield normal fragments that are between ~1.1 kb to 3.4 kb for easy visualization of larger fragments containing large CTG repeats.

Gene Link GeneProber™ GLDMDig2 [40-2026-41] DM Southern Blot Fragment Analysis




Human genomic DNA was digested with BamHI, Pstl, BgII or EcoRI. After electrophoretic separation, the agarose gels were processed for non-radioactive Southern blot analysis using Gene Link's GLDMDig2 GeneProber™ as described in the procedure section of this manual. Sizing of fragments compared to molecular weight markers and control fragment pattern assist in genotyping the approximate range of CTG repeats of the DMPK gene.

DMPK Gene Normal Southern Blot Fragment Analysis Pattern Restriction Digestion*		
Restriction Enzyme	Normal Fragment Size	
Eco RI	~8.9 or/and 9.9 kb	
Bgl I	~3.4 kb	
Bam HI	~1.37 kb	
Pst I	~1.13 kb	
*Probed with Gene Link DMPK CTG repeat region specific probes GL DMDig2, DM3 or DM4.		



Gene Link Myotonic Dystrophy GeneProber™



Myotonic Dystrophy Molecular Analysis & Results Interpretation of CTG Repeats Genotyping					
Clinical Category	Normal (male/female)	Intermediate Allele Mild	DM Allele with Classical Condition	DM Allele with Congenital Condition and mental retardation	
Risk mutation will become full mutation in next generation	0%	moderate	significant	high	
Number of CTG repeats	5-27	50-100	100-1000	>1000	
Size of CTG repeats; bp	15-81	150-300	300-3000	>3000	
Total Fragment Size; bp	128-194	267-413	428-1328	>1328	

There are no definite repeat size boundaries for the three clinical groups and there are overlaps between the groups. A trimodal distribution is observed in European populations, with (CTG)₅ being the most frequently occurring allele, alleles of 11,12,13 and 14 make up the second mode and the final mode represents alleles of 19 and above.

Myotonic Dystrophy Genemer™ & GScan™ Results & Interpretation

The results obtained from the genetic fragment analyzer will approximately show the fragment size amplified, based on these results an interpretation can be made about the genotype of the sample. It is known that there is an overlap between the normal and DM allele sizes. The repeat sizes obtained falling in the overlap region should be preferably repeated and possibly run with more samples from other family members. Refer to the table 2 for determining the CTG repeats and fragment size expected. The formula for determining PCR fragment size is 113 + 3n, where n= the number of CTG repeats.

The results obtained from agarose gel electrophoretic pattern will approximately show the fragment size amplified, based on these results an interpretation can be made about the genotype of the sample. It is known that there is an overlap between the normal and DM allele sizes. The repeat sizes obtained falling in the overlap region should be preferably repeated and possibly run with more samples from other family members. Refer to the table 2 for determining the CTG repeats and fragment size expected. The formula for determining PCR fragment size is 113 + 3n, where n= the number of CTG repeats.




Gene Link DM Genemer™ Kit [40-2026-11] Agarose Gel Amplified Fragment Analysis

1 kb 750 bp 500 bp 400 bp

300 bp

100 bp



Lanes 1-4 are chromosomal DNA samples from a family and represent ~6 CTG repeats (~131 bp) and ~12 CTG repeats of ~149 bp fragment. Lanes 5-7 are Genemer Control DNA samples as follows.


Lane 5; DM Genemer Control DNA; 40-2026-01; ~12 CTG repeats of CTG repeats of CTG repeats (~12 CTG repeats ~12 CTG

DM Genemer CTG Repeat Amplification


Lane 5; DM Genemer Control DNA; 40-2026-01; ~12 CTG repeats Lane 6; DM Genemer Control DNA; 40-2026-02; ~45 CTG repeats Lane 5; DM Genemer Control DNA; 40-2026-05; ~182 CTG repeats

DM GScanTM V2 reactions performed on various human genomic samples of known large repeats of human genomic DNA. 10 μ L aliquots were electrophoresed on a 2% agarose gel and stained with ethidium bromide. Approximate CTG repeats of samples from lane 11 to lane 19 are as follows; 11/75; 5/60; 24/80; 15/150; 5/160; 5/185;13/200; 10/?? and 10/380.

After DM GScan[™] PCR amplification, 10 μ l of the reaction was directly loaded to a 2% TAE agarose gel containing ethidium bromide. Details of samples genotype is given above.



DM GScan™ V2 reactions performed on various human genomic samples of known large repeats of human genomic DNA. Samples were processed for fragment analysis of ABI3130xl. Panel 1 shows a sample with a ~5/70 CTG repeat, panel 2 shows a sample with a ~13/140 CTG repeat.



Required reagents with recommended suppliers

Roche Applied Science http://www.roche	e-applied-science.com
Product Description	Catalog Number
Nylon Membranes, positively charged ; 20 sheets 10 x 15 cm	11209272001
DNA Molecular Weight Marker III, DIG-labeled ; 500 μl 10 μg/ml 5 μg	11218603910
DIG Easy Hyb ; 500 mL	11603558001
IG Wash and Block Buffer Set ; 1 set 30 blots	11585762001
nti-Digoxigenin-AP, Fab fragments from sheep; 200 μL 150 U	11093274910
DP Star Ready to use; 2X 50 mL	12041677001

Gene Link http://www.genelink.com/geneprodsite/category.asp?c=44				
Non-radioactive Southern Blot Reagents				
Product Description	Catalog No.	Unit Size		
Agarose LE Molecular Biology Grade 100 gms	40-3010-10	100 gms		
TAE Buffer 50 X Concentrate 1000 mL	40-3007-10	1 L		
TBE Buffer 5 X Concentrate; 1L	40-3008-10	1 L		
Loading buffer 10X BPB/XC non-denaturing; 1mL	40-3003-10	1 mL		
Loading buffer 10X BPB/XC non-denaturing ; 15 mL	40-3003-15	15 mL		
Lumisol II, Hybridization Solution; 200 mL	40-5023-20	200 mL		
Depurination Solution (2X) for Southern Blotting; 1 L	40-5034-10	1 L		
Denaturation Solution (2X) for Southern Blotting; 1L	40-5035-10	1 L		
Neutralization Solution (2X) for Southern Blotting; 1L	40-5036-10	1 L		
Hybwash A; Hybridization Wash Solution Concentrate (20X SSC); 250 mL	40-5020-25	250 mL		
Hybwash B, Hybridization Wash Solution (10% SDS); 100 mL	40-5021-10	100 mL		
Maleic acid buffer 10X (Buffer M 10X); 200 mL	40-5025-20	200 mL		
10% Blocking Reagent; 100 mL	40-5026-10	200 mL		
Detection Buffer 10X; Alkaline Phosphatase detection buffer; 100 mL	40-5031-10	100 mL		
CDP-Star® Substrate; Ready-to-Use 0.25 mM in spray bottle; 10 mL	40-5010-10	10 mL		



Reagent Preparation

Most reagents with composition listed below are available in a molecular biology laboratory or these can be prepared in house. Gene Link catalog numbers are also listed if you like to purchase these common reagents.

Depurination Solution (0.25M HCI)			
Product Description	Catalog No.	Volume	
Depurination Solution (2X) for Southern Blotting	40-5034-10	150 mL	
Sterile water		150 mL	
Total Volume		300 mL	

Denaturation Solution (0.5M NaOH, 1.5M NaCl)				
Product Description	Catalog No.	Volume		
Denaturation Solution (2X) for Southern Blotting	40-5035-10	150 mL		
Sterile water		150 mL		
Total Volume		300 mL		

Neutralization Solution (0.5M Tris-HCl pH 7.5, 1.5M NaCl)		
Product Description	Catalog No.	Volume
Neutralization Solution (2X) for Southern Blotting	40-5036-10	150 mL
Sterile water		150 mL
Total Volume		300 mL

Hybwash I		
(2xSSC, 0.1% SDS)		
Product Description	Catalog No.	Volume
Hybwash A; Hybridization Wash Solution Concentrate (20X SSC)	40-5020-25	35 mL
Sterile water		311 mL*
Hybwash B, Hybridization Wash Solution Concentrate (10% SDS)	40-5021-10	4 mL*
Total Volume		350 mL
* Volumes adjusted to whole numbers		

Hybwash II (0.5xSSC, 0.1%SDS)		
Product Description	Catalog No.	Volume
Hybwash A; Hybridization Wash Solution Concentrate (20X SSC)	40-5020-25	9 mL*
Sterile water		337 mL
Hybwash B, Hybridization Wash Solution Concentrate (10% SDS)	40-5021-10	4 mL*
Total Volume		351 mL
* Volumes adjusted to whole numbers		

1X Maleic Acid Buffer (Buffer M 1X) (100 mM Maleic acid, 150 mM NaCl pH7.5)		
Product Description	Catalog No.	Volume
Maleic acid buffer 10X (Buffer M 10X)	40-5025-20	10 mL
Sterile water		90 mL
Total Volume		100 mL

Buffer MB (1 x Maleic acid buffer (Buffer M) with Blocking Reagent) Always prepare fresh!		
Product Description	Catalog No.	Volume
Maleic acid buffer 10X (Buffer M 10X)	40-5025-20	10 mL
Sterile water		80 mL
10% Blocking Reagent*	40-5026-10	10 mL
Total Volume		100 mL

The prepared reagent will be turbid yellow in color

1X Detection Buffer, Alkaline phosphatase detection buffer (100mM Tris-HCl pH 9.5, 100mM NaCl)		
Product Description	Catalog No.	Volume
Detection Buffer 10X; Alkaline phosphatase detection buffer	40-5031-10	10 mL
Sterile water		90 mL
Total Volume		100 mL



^{*} The 10% Blocking Reagent is turbid yellow in color and will form precipitates on storage. Warm to 50°C and shake well before aliquoting. DO NOT SHAKE VIGOROUSLY

Appendix: Protocols

Genomic DNA Purification

Genomic DNA is usually extracted from blood. A simple procedure is given below that purifies $^{\sim}10~\mu g$ DNA from 300 μl blood using a 30 minute procedure.

Omni-Pure™ Genomic DNA Purification System Catalog Number: 40-4010-01 Rapid DNA Purification Protocol for 300 µl Whole Blood

A. Initial Preparation

- 1. Label two sets of 1.5 ml tubes per sample.
- 2. Add 900 μ l GD-1 solution (RBC Lysis Solution) to one tube for each sample.
- 3. Add 300 µl Isopropanol (2-propanol) to one tube for each sample. Cap the tubes.

B. Cell Lysis

- 1. To the tube containing 900 μ l GD-1 solution (RBC Lysis Solution) using a filter tip pipet transfer 300 μ l whole blood. Cap and gently mix by inversion. Incubate for 1-3 minutes at room temperature. Mix by inversion a few times during this incubation period. Incubate longer for fresh blood cells as they are intact and not lysed already.
- 2. Centrifuge at 3 K rpm for 20 seconds to pellet the white blood cells. A reddish white pellet should be clearly visible. Decant and discard supernatant leaving behind the last few droplets. Do not totally remove the supernatant.
- 3. Completely resuspend the white blood cell pellet by vigorously vortexing the tube. Ensure that the pellet is completely resuspended.
- 4. To the resuspended cells add 300 μ l GD-2 solution (Cell Lysis Solution). Mix by gentle vortexing. You will notice release of DNA by the thickening of the liquid in the sample. Samples may be stored at this stage for processing later. It has been shown that the samples are stable in Cell Lysis Solution for at least 2 years at room temperature.

C. Protein Precipitation

- 1. Add 100 µl GD-3 solution (Protein Precipitation Solution) to the sample in cell lysis solution.
- 2. Vortex vigorously for 20 seconds. Small particles of brown color will appear and be visible at this stage.
- 3. Centrifuge at 5 K rpm for 1 minute to pellet the precipitated proteins. A clearly visible brown pellet containing proteins should be collected at the bottom of the tube.

D. DNA Precipitation

- 1. Decant the supernatant containing the DNA to a new appropriately labeled tube (see initial preparation above) containing 300 µl 100% Isopropanol (2-propanol).
- 2. Mix the sample by inversion until a visible white floating DNA strand-particle is identified. Mixing by inversion 30-40 is usually sufficient.
- 3. Centrifuge at 6 K rpm for 1 minute to collect the DNA as a pellet. A white DNA pellet should be clearly visible.
- 4. Decant supernatant and place tube inverted on a clean Kimwipe™ tissue paper to drain the remaining supernatant.
- 5. To remove residual salts, add 300 µl of 70% ethanol. Vortex gently.
- 6. Centrifuge at 6 K rpm for 1 minute to collect the DNA as a pellet. Gently take out the tubes so that the pellet is not dislodged. While holding the tube, rotate tube so that you can watch the pellet. Now carefully decant the ethanol, keeping an eye on the pellet so that it does not flow away.
- 7. Place tube inverted on a clean Kimwipe™ tissue paper to drain the remaining ethanol.
- 8. Air dry the DNA pellet. Do not use vacuum.

E. DNA Reconstitution & Use

- 1. Add 100 μ l of GD-4 solution (DNA Reconstitution Solution). Vortex gently. Incubate at 60°C for 5 minutes to facilitate dissolution or keep overnight at room temperature.
- 2. Store DNA at 4 °C. For long-term storage, place sample at -20 °C or -80 °C.
- 3. Average yield of 10 μg is expected from 300 μl blood DNA. The range is between 5 μg to 15 μg .
- 4. The 100 µl of purified DNA obtained will have an average concentration of ~ 100 ng/µl.
- 5. For PCR amplification use 1-2 μl.
- 6. Use 100 µl for restriction digestion followed by Southern blot analysis.
- 7. It is convenient to perform multiple 300 µl blood DNA purification instead of scaling up the procedure.



Myotonic Dystrophy Product Ordering Information

Product	Unit Size	Catalog No.
Myotonic Dystrophy Genemer™ Primer pair Primers for amplification of CTG triple repeat spanning region. The quantity supplied is sufficient for 400 regular 50 μL PCR reactions.	10 nmols	40-2026-10
Myotonic Dystrophy GeneProber™ GLDM1 Probe unlabeled Myotonic dystrophy CTG triple repeat spanning region unlabeled probe for radioactive labeling and Southern blot detection of Bam HI digested DNA.	500 ng	40-2026-40
Myotonic Dystrophy GeneProber™ GLDM2 Probe unlabeled Myotonic dystrophy CTG triple repeat spanning region unlabeled probe for radioactive labeling and Southern blot detection of Pst I digested DNA.	500 ng	40-2026-39
Myotonic Dystrophy GeneProber™ GLDMDig1 Probe Digoxigenin labeled Myotonic Dystrophy CTG triple repeat spanning region digoxigenin labeled probe for non- radioactive Southern blot detection.	110 μL	40-2026-41
Myotonic Dystrophy PCRProber ™ AP labeled probe Alkaline phosphatase labeled probe	12 μL	40-2026-31
Myotonic Dystrophy PCRProber ™ Kit for chemiluminescent detection Kit for performing PCR amplification and chemiluminescent based detection.	5 blots [50 rxns]	40-2026-32
GLDM Genemer™ Kit for Radioactive Detection Kit for amplification and radioactive detection of Myotonic Dystrophy CTG triple repeat region amplified PCR products using ³⁵ S or ³² P. 100 Reactions.	1 Kit [100 rxns]	40-2026-20
GLDM GScan Kit for fluorescent detection Kit for performing fluorescent PCR amplification based detection. Various dye kits. XX=FM for 6-Fam; HX for Hex; TT for Tet; C3 for Cy3 and C5 for Cy5.	1 Kit [100 rxns]	40-2026-15XX

Genemer™ GScan Control DNA Cloned fragment of the mutation region of a particular gene. These control DNA's are ideal genotyping templates for optimizing and performing control amplification with unknown DNA. The size of the triple repeats has been determined by sequencing and gel electrophoresis. The stability of size repeats upon cloning and amplification has NOT been determined. Thus, the size should be considered approximate and there is no claim for each fragment to contain the exact number of triple repeats. These control DNA's are sold with the express condition that these NOT be used for exact triple repeat size determination of DNA of unknown genotype. The control DNA should be used for determining the performance of specific Genemer™ and PCRProber™ Gene Link products.

GLDM 12 ~CTG repeat Genemer™ Control DNA	500 ng	40-2026-01
GLDM 45 ~CTG repeat Genemer™ Control DNA	500 ng	40-2026-02
GLDM 93 ~CTG repeat Genemer™ Control DNA	500 ng	40-2026-03
GLDM 129 ~CTG repeat Genemer™ Control DNA	500 ng	40-2026-04
GLDM 194 ~CTG repeat Genemer™ Control DNA	500 ng	40-2026-05

All Gene Link products are for research use only



Product	Catalog No.	Unit Size
Agarose Tablets, 0.5 gm each; 100 tablets	40-3011-10	100 tablets
Agarose LE Molecular Biology Grade; 100 g	40-3010-10	100 g
Agarose LE Molecular Biology Grade; 500 g	40-3010-50	500 g
Hybwash A, Hybridization Wash Solution (20X SSC); 200 mL	40-5020-20	200 mL
Hybwash B, Hybridization Wash Solution (10% SDS); 100 mL	40-5021-10	100 mL
TAE Buffer; 50 X Concentrate; 100 mL	40-3007-01	100 mL
TAE Buffer; 50 X Concentrate; 1 L	40-3007-10	1 L
TBE Buffer; 5 X Concentrate; 1 L	40-3008-10	1 L
Buffer M 10X (Maleic Acid buffer); 100 mL	40-5025-10	100 mL
10% Blocking solution; 100 mL	40-5026-10	100 mL
Loading Buffer 2X BPB/XC Denaturing for Sequencing; 1 mL	40-5027-10	1 mL
10x AP Detection buffer (alkaline phosphatase detection buffer); 100 mL	40-5031-10	100 mL
Lumisol™ I Hybridization Solution; contains formamide; 200 mL	40-5022-20	200 mL
Lumisol™ II Hybridization Solution; for non-toxic hybridizations; 200 mL	40-5023-20	200 mL
Lumisol™ III Hybridization Solution; for oligo probes; 200 mL	40-5024-20	200 mL
CDP-Star® Substrate; Ready-to-Use 0.25 mM in spray bottle; 10 mL	40-5010-10	10 mL

Loading Buffers		
Product	Catalog No.	Size
Gel Loading Buffer 5X BPB/XC non-denaturing; 1 mL	40-3002-10	1 mL
Gel Loading Buffer 5X BPB/XC non-denaturing; 15 mL	40-3002-15	15 mL
Gel Loading Buffer 10X BPB/XC non-denaturing; 1 mL	40-3003-10	1 mL
Gel Loading Buffer 10X BPB/XC non-denaturing; 15 mL	40-3003-15	15 mL
Gel Loading Buffer 5X Orange G/XC non-denaturing; 1 mL	40-3004-10	1 mL
Gel Loading Buffer 5X Orange G/XC non-denaturing; 15 mL	40-3004-15	15 mL
Gel Loading Buffer 2X BPB/XC Denaturing for Sequencing; 1 mL	40-5027-10	1 mL
Gel Loading Buffer 2X BPB/XC Denaturing for Sequencing; 15 mL	40-5027-15	15 mL
DNA SDS Gel Loading Buffer 5X BPB/XC DNA binding protein denaturing buffer ; 1 mL	40-5028-10	1 mL
DNA SDS Gel Loading Buffer 5X BPB/XC DNA binding protein denaturing buffer; 15 mL	40-5028-15	15 mL
RNA Gel Loading Buffer 2X BPB/XC with ethidium bromide; 1 mL	40-5029-10	1 mL
RNA Gel Loading Buffer 2X BPB/XC with ethidium bromide; 15 mL	40-5029-15	15 mL
RNA Gel Loading Buffer 2X BPB/XC without ethidium bromide ; 1 mL	40-5030-10	1 mL
RNA Gel Loading Buffer 2X BPB/XC without ethidium bromide; 15 mL	40-5030-15	15 mL

All Gene Link products are for research use only



Related Products Ordering Information

Omni-Pure™ DNA & RNA Purification Systems			
Product	Catalog No.	Unit Size*(Purifications)	
Omni-Pure™ Blood DNA Purification System	40-4010-01	100	
Omni-Pure™ Blood DNA Purification System	40-4010-05	500	
Omni-Pure™ Blood DNA Purification System	40-4010-10	1000	
Omni-Pure™ Tissue DNA Purification System	40-4050-01	100	
Omni-Pure™ Tissue DNA Purification System	40-4050-05	500	
Omni-Pure™ Tissue DNA Purification System	40-4050-10	1000	
Omni-Pure™ Plant DNA Purification System	40-4060-01	100	
Omni-Pure™ Plant DNA Purification System	40-4060-05	500	
Omni-Pure™ Plant DNA Purification System	40-4060-10	1000	
Omni-Pure™ Viral DNA Purification System	40-3720-01	100	
Omni-Pure™ Viral DNA Purification System	40-3720-05	500	
Omni-Pure™ Microbial DNA Purification System	40-3700-01	100	
Omni-Pure™ Microbial DNA Purification System	40-3700-05	500	
Omni-Pure™ Viral RNA Purification System	40-3650-01	100	
Omni-Pure™ Viral RNA Purification System	40-3650-05	500	

^{*}Sample volume for each purification system varies. Each purification yields sufficient quantity for desired applications.

Catalog No.	Unit Size*(Purifications)
	omeone (i dimedions)
40-4110-10	100
40-4110-50	500
40-4120-10	100
40-4120-50	500
40-4130-10	100
40-4130-50	500
40-4140-10	100
40-4140-50	500
	40-4110-50 40-4120-10 40-4120-50 40-4130-10 40-4130-50 40-4140-10

 $[\]hbox{*Sample volume for each purification system varies. Each purification yields sufficient quantity for desired applications.}$

Omni-Pure™ Plasmid DNA Purification Systems	
Catalog No.	Unit Size*(Purifications)
40-4020-01	100
40-4020-05	500
	Catalog No. 40-4020-01

^{*}Sample volume for each purification system varies. Each purification yields sufficient quantity for desired applications.

All Gene Link products are for research use only



Document Warranty and Liability

Information in this document is subject to change without notice. This document and all information presented in this document are written as a guide. Gene Link, Inc. does not warrant this document to be free of errors and assumes no responsibility for any errors that may appear in this document.

Gene Link disclaims all warranties with respect to this document, expressed or implied, including but not limited to those of merchantability or fitness for a particular purpose. In no event shall Gene Link be liable, whether in contract, tort, warranty, or under any statute or on any other basis for special, incidental, indirect, punitive, multiple or consequential damages in connection with or arising from this document, including but not limited to the use thereof.

Website

As the receipt of information on the Internet is highly dependent upon factors, including without limitations to, the user's computer, browser, operation system, etc., information may be perceived incorrectly. Therefore, Gene Link does not warrant or guarantee that the information contained on its website www.genelink.com is error free.

Product Warranty and Liability

Warranty: Gene Link makes no warranty of any kind, specifically disclaims and excludes all other warranties of any kind or nature, directly or indirectly, express or implied, including, without limitation, as to the suitability, productivity, durability, fitness for a particular purpose or use, merchantability, condition, or any other matter with respect to Gene Link products. Gene Link products are for research purposes only including custom products. There is no warranty or claim of its performance for any specific research application. All Gene Link products are guaranteed to meet or exceed the specifications stated. Each Gene Link product is shipped with documentation stating specifications and other technical information. If the product fails to meet the stated specifications the sole remedy is prompt replacement by Gene Link or within 30 days of purchase a refund of the purchased price.

Liability: Under no circumstances shall Gene Link be liable for any damages directly or indirectly related to Gene Link's products and services. Whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or the failure of Gene Link products to perform in accordance with the stated specifications.

Research Use Only. Not for use in diagnostic or clinical procedures.

Notice to Purchaser: The purchase of this product conveys to the purchaser the limited, non-transferable right to use the purchased amount of the product only to perform internal research for the sole benefit of the purchaser. No right to resell this product or any of its components is conveyed expressly, by implication, or by estoppel. This product is for internal research purposes only and is not for use in commercial applications of any kind, including, without limitation, quality control and commercial services such as reporting the results of purchaser's activities for a fee or other form of consideration. For information on obtaining additional rights, please contact sales@genelink.com.

© 2015 Gene Link Inc. All rights reserved.

The trademarks mentioned herein are the property of their respective owners.

Gene Link, Inc. 190 Saw Mill River Road Hawthorne, NY 10532 USA

Tel: (914) 769-1192

Email: support@genelink.com

www.genelink.com



